The level of amyloid (white shades in area encircled by green dotted lines) – the protein thought to drive neurodegeneration in AD, is high in the brain of AD mouse (left) and reduces after the administration of the genome editing therapy throughout the brain (right).
An international research team led by scientists from the Hong Kong University of Science and Technology (HKUST) has developed a novel strategy using brain-wide genome-editing technology that can reduce Alzheimer’s disease (AD) pathologies in genetically modified AD mouse models. This advanced technology offers immense potential to be translated as a novel long-acting therapeutic treatment for AD patients.
In China alone, over 500,000 patients are estimated to be living with a hereditary form of AD – familial Alzheimer’s disease (FAD), which is a congenital form of AD highly associated with family history. Although FAD has a clear genetic cause and can be diagnosed before cognitive problems occur, no effective treatment currently exists.
There is enormous potential in the use of genome-editing technology1 as therapeutic strategies for diseases caused by inherited mutations, such as FAD. It is especially useful for correcting disease-causing genetic mutations before symptoms appear, for which it is considered a “once-and-for-all” treatment as its effects can last a lifetime. However, several hurdles have prevented its clinical development and application – most notably the lack of an effective, efficient, and non-invasive means to deliver genome-editing agents into the brain. Furthermore, existing genome-editing technologies are unable to generate beneficial outcomes throughout the whole brain.
Recently, a team led by Prof. Nancy Ip, Vice-President for Research and Development at HKUST, developed a new genome-editing system that not only crosses the blood–brain barrier, but also delivers an optimized genome-editing tool to the entire brain. Using a newly engineered delivery vehicle for genome-editing, this strategy achieves efficient brain-wide genome editing through a single non-invasive intravenous administration. This effectively disrupts FAD-inflicted mutations in AD mouse models and ameliorates AD pathologies throughout the entire brain, paving the way to novel therapeutic development for the disease.
Meanwhile, the research team also found in the mouse models that the level of amyloid, a protein thought to drive neurodegeneration in AD, remained low for 6 months post-treatment (about 1/3 of their normal lifespan), demonstrating that this single-shot genome-editing strategy has lasting effects. More importantly, no side effects were detected so far in the mice.
“As the first demonstration of efficient brain-wide genome editing to alleviate Alzheimer’s disease pathology throughout the whole brain, this is really an exciting development,” said Prof. Ip, who is also the Morningside Professor of Life Science and Director of the State Key Laboratory of Molecular Neuroscience at HKUST. “Our work is an important milestone for the use of genome editing in treating hereditary brain diseases, and contributes to the development of precision medicine for inherited forms of neurodegenerative diseases.”
This research was a collaborative effort among scientists from HKUST; the California Institute of Technology; and the Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences. The results were recently published in Nature Biomedical Engineering.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Scientists Completed the First Human Genome 20 Years Ago. How Far Have We Come, and What’s Next?
Massive global consortiums, including the 1000 Genomes Project, the Cancer Genome Atlas, the BRAIN Initiative ... Using a popular method called GWAS (genome-wide association study), scientists are ...
- Large-scale genetic repeat variations contribute to height and other human traits
New study finds that a type of genetic modification involving long, repeated sequences within the human genome can affect a variety of health-related traits. Over the last decade, geneticists ...
- Microbiome CDMO, List Labs, Partners with Genome And Company, to Create Global Microbiome Research, Development, and Manufacturing Powerhouse
21, 2021 /PRNewswire/ -- In an unprecedented collaboration, premier microbiome CDMO List Labs partners with leading global clinical stage biotechnology company, Genome ... for a wide range of ...
- Cas9 News and Research
The common analogy for CRISPR gene editing ... wide range of questions, from how organisms develop to how the nervous system drives behavior. Researchers from MIT, the McGovern Institute for Brain ...
- UNC-Chapel Hill researchers awarded $9.25M to study DNA variance related to disease
The study will determine whether variants act differently in males and females; in the brain, liver ... expertise of the study investigators in genome-wide association studies, statistical ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Genome-edited tomato enters Japanese market
The 'Sicilian Rouge High GABA' is a unique tomato variety. This variety contains high levels of gamma aminobutyric acid, which is said to help people relax and can keep blood pressure ...
- Advancements In The Field of Genome Editing Have Facilitated Increased Adoption of Vector-Based CRISPR Genes
As the COVID-19 pandemic tightens its grip on the world, healthcare providers and practitioners are racing against time to find reliable diagnosis and cures for the deadly disease. The pandemic has ...
- Discovery Points Toward the Next Revolution in Genome Editing Technology
New Programmable Gene Editing Proteins Found Outside of CRISPR Systems Researchers find RNA-guided enzymes are more diverse and widespread than previously believed. Within the last decade, scientists ...
- RAG Represents a Widespread Threat to the Lymphocyte Genome
The RAG1 endonuclease, together with its cofactor RAG2, is essential for V(D)J recombination but is a potent threat to genome stability. The sources of RAG1 mis-targeting and the mechanisms that have ...
- Creative Biogene Offers One-Stop Customized CRISPR Based Microbe Genome Editing Service
Creative Biogene Offers One Stop Customized CRISPR Based Microbe Genome Editing Service for global clients New York United States August 18 2021 Creative Biogene has been dedicated itself to ...